PUBLISHER: IMARC | PRODUCT CODE: 1561447
PUBLISHER: IMARC | PRODUCT CODE: 1561447
The global radiotherapy market size reached US$ 6.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.7 Billion by 2032, exhibiting a growth rate (CAGR) of 3.9% during 2024-2032. The rise in cancer incidence, advancements in technology, increasing precision in tumor targeting, growing healthcare expenditure, and heightened awareness of radiotherapy's benefits as a non-invasive cancer treatment option are some of the factors creating a positive outlook for the market growth.
Technological advancements
Radiotherapy market recent developments and innovations such as intensity-modulated radiotherapy (IMRT) and image-guided radiotherapy (IGRT) have greatly improved the precision and effectiveness of cancer treatments, aiding in market expansion. IGRT involves the use of real-time imaging during radiation therapy sessions, ensuring that the tumor is accurately targeted, even if there is movement between treatments. This allows oncologists to modulate the radiation dose by varying the beam intensity during treatment, effectively conforming the radiation dose to the shape of the tumor while minimizing exposure to surrounding healthy tissues. Moreover, in April 2020, the IAEA started a project to study how Stereotactic Fractionated Radiotherapy (SFRT) can enhance palliative treatment for lung and cervical cancers, aiming to alleviate symptoms and slow down disease progression, which is further aiding in market expansion.
Integration of artificial intelligence (AI) in radiotherapy
AI technologies are being used to streamline the planning process, improve the accuracy of radiation dosing, and optimize treatment schedules. Machine learning (ML) algorithms can analyze large datasets of imaging and treatment records to identify patterns and predict optimal treatment approaches tailored to individual patients. AI is also being utilized to develop predictive models for patient responses to various radiation therapies, which can be used in adaptive radiotherapy to adjust treatments based on the patient's response to ongoing sessions. Radiologists look at approximately 225,000 MRI/CT exams in 40 years, while AI can start with 225,000 scans to train itself and reach millions of scans within a very short period of time. This will streamline operations and expand healthcare services to a larger population, thereby boosting radiotherapy market revenue.
Shift toward personalized medicine
The growing shift towards personalized medicine in cancer treatment is increasingly influencing the radiotherapy market. Personalized medicine approaches involve tailoring medical treatment to the individual characteristics of each patient, and in the context of radiotherapy, this means customizing radiation doses and schedules based on genetic, phenotypic, and environmental factors that could affect treatment response. Healthcare providers can reduce the incidence of unfavorable side effects and increase treatment efficacy by concentrating on individualized patient care. The Personalized Medicine Coalition's report indicates that the number of personalized medicines in the US market doubled between 2016 and 2020. These medicines, which accounted for 25% of new drugs approved by the FDA in 2019, rose from 132 to 286, marking a significant increase from 5% in 2005. This growth is boosting the radiotherapy market share.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on type, application, and end user.
External beam radiation therapy accounts for the majority of the market share
The report has provided a detailed breakup and analysis of the market based on the type. This includes external beam radiation therapy (intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), tomotherapy, stereotactic radiosurgery, stereotactic body radiation therapy, proton therapy, 3D conformal radiotherapy (3D CRT), and volumetric modulated arc therapy (VMAT)), internal radiation therapy/brachytherapy and systemic radiation therapy. According to the report, external beam radiation therapy represented the largest segment.
Based on the radiotherapy market analysis, the surging demand for external beam radiation therapy (EBRT) is driven by its versatility and effectiveness in treating a wide range of cancers with precision. In line with this, EBRT remains the most common form of radiotherapy due to its ability to accurately target tumors with high-energy beams, minimizing damage to surrounding healthy tissues. Furthermore, the introduction of technologically advanced systems like three-dimensional (3D) conformal radiation therapy, intensity-modulated radiation therapy (IMRT), and stereotactic body radiation therapy (SBRT) has greatly enhanced the appeal of EBRT, creating a positive outlook for market expansion.
Breast cancer holds the largest share of the industry
A detailed breakup and analysis of the market based on the application have also been provided in the report. This includes skin and lip cancer, head and neck cancer, breast cancer, prostate cancer, cervical cancer, lung cancer, and others. According to the report, breast cancer accounted for the largest market share.
Radiotherapy's efficacy as a standard post-operative therapeutic strategy to prevent tumor recurrence in breast cancer represents a crucial factor driving its market demand. According to the World Health Organization (WHO), there were 2.3 million women diagnosed with breast cancer and 670,000 deaths globally in 2022. This increasing incidence of breast cancer globally necessitates effective treatment modalities, and radiotherapy is recognized for its critical role in the early and advanced stages of the disease. It is particularly effective in conserving the breast in cases of early-stage breast cancer, often used following lumpectomy to eliminate any remaining cancerous cells and significantly reduce the risk of cancer returning. Additionally, radiotherapy also helps alleviate symptoms and control tumor growth in advanced metastatic cases, which is further boosting its demand.
Ambulatory and radiotherapy centers represent the leading market segment
The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, cancer research institutes, and ambulatory and radiotherapy centers. According to the report, ambulatory and radiotherapy centers represented the largest segment.
As per the radiotherapy market report, its demand in ambulatory and radiotherapy centers is driven by an increasing preference for outpatient care settings, which offer cost-efficiency, convenience, and reduced patient burden compared to in-hospital treatments. Ambulatory care centers are particularly appealing because they enable patients to receive high-quality, specialized care without the need for overnight hospital stays. Additionally, these centers can often provide services at a lower cost than traditional hospital settings due to their specialized nature and efficiency in managing specific treatments like radiotherapy. This cost-effectiveness attracts patients and healthcare payers seeking to manage expenditures. Furthermore, the proliferation of radiotherapy centers and technological advancements that make sophisticated radiotherapy equipment more compact and affordable, are propelling the market forward.
North America leads the market, accounting for the largest radiotherapy market share.
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for radiotherapy.
The demand for radiotherapy in North America is propelled by numerous factors such as well-established healthcare infrastructure, robust funding for cancer research, and the high prevalence of cancer. North America boosts some of the world's leading cancer research facilities and hospitals, which adopt and also develop cutting-edge radiotherapy technologies. In addition to this, the region benefits from substantial healthcare spending both from the public and private sectors, allowing for significant investments in advanced medical equipment and treatment modalities. Furthermore, there is a strong focus on early cancer detection and screening programs, which identify patients who can benefit from early intervention using radiotherapy, which is impelling the market growth.
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)